Barbagallo 2014.
Study characteristics | ||
Study design | Cohort | |
Study setting | Setting: Department of Neurosurgery, Policlinico "G. Rodolico" Policlinico "G. Rodolico" University Hospital, University of Catania Country: Italy Dates: surgery between 2004 and 2012 |
|
Selection of participants | All people underwent surgery for primary GBM with the aid of neuronavigation, and all but 2 people received gross tumour resection. The study was aimed at comparing short‐term vs long‐term TMZ treatment (people who received > 6 cycles), therefore some data were given as group A vs group B based on duration of treatment. | |
Participant characteristics | Sample size: 37 (deaths: NR) Age: mean 60.4, SD 11.8; range 30–82 years Sex: 51.4% men KPS: mean 67.1, SD 15.2 |
|
Tumour characteristics | GBM: 100% First diagnosis: 100% Biopsy: 0%; subtotal resection: 5.4%; total resection: 94.6% IDH1 wild‐type: NR; IDH2 wild‐type: NR |
|
Treatment regimen | Stupp protocol. For adjuvant TMZ therapy, people in Group A received TMZ every 28 days for > 6 cycles (up to 101), those in Group B were treated with the same adjuvant TMZ dose regimen for ≤ 6 cycles. | |
MGMT promoter methylation tests implemented | MSP, PSQ | |
Dates and follow‐up | Timing of MGMT assessment: NR Start time for follow‐up: date of surgery; follow‐up: median NR; range NR |
|
Notes |